![](/img/cover-not-exists.png)
Peginterferon alfa-2A (40 KD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose
S.J. Hadziyannis, H. Cheinquer, T. Morgan, M. Diago, D.M. Jensen, H. Sette Jr., G. Ramadori, H.C. Bodenheimer, P. Marcellin, S.-D. Lee, P.J. Roberts, A.M. AckrillVolume:
36
Year:
2002
Language:
english
DOI:
10.1016/s0168-8278(02)80001-0
File:
PDF, 147 KB
english, 2002